Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Artelo Biosciences, Inc. ARTL
$1.68
-$0.01 (-0.75%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
4797559.00000000
-
week52high
7.20
-
week52low
1.39
-
Revenue
0
-
P/E TTM
0
-
Beta
0.91557000
-
EPS
-3.47000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 12 авг 2022 г. |
| HC Wainwright & Co. | Buy | 01 ноя 2021 г. | |
| Ladenburg Thalmann | Buy | 12 февр 2021 г. | |
| Maxim Group | Buy | Hold | 07 янв 2021 г. |
| Maxim Group | Hold | Buy | 25 ноя 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Gorgas Gregory D. | A | 85000 | 85000 | 01 февр 2023 г. |
| Gorgas Gregory D. | A | 2400 | 1200 | 12 авг 2022 г. |
| Gorgas Gregory D. | A | 1200 | 1200 | 11 авг 2022 г. |
| MATSUI CONNIE | A | 10000 | 10000 | 24 июн 2022 г. |
| Kelly Steven | A | 10000 | 10000 | 24 июн 2022 г. |
| EMANUELE ROBERT MARTIN | A | 10000 | 10000 | 24 июн 2022 г. |
| Reyes Gregory | A | 10000 | 10000 | 24 июн 2022 г. |
| SEYMOUR TAMARA A | A | 10000 | 10000 | 24 июн 2022 г. |
| Blayney Douglas | A | 10000 | 10000 | 24 июн 2022 г. |
| Gorgas Gregory D. | A | 1355000 | 1355000 | 03 дек 2021 г. |
Новостная лента
Artelo Biosciences to Present at MicroCap Rodeo's Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 22, 2023
Accesswire
15 февр 2023 г. в 08:30
SOLANA BEACH, CA / ACCESSWIRE / February 15, 2023 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it has been invited to present at MicroCap Rodeo's Third Annual Winter Wonderland - Best Ideas Virtual Investor conference, which is being held virtually on February 21st - 24th, 2023. Gregory D.
Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd
GlobeNewsWire
26 янв 2023 г. в 08:30
CEO Gregory Gorgas to discuss developments related to the Company's Cancer Appetite Recovery Study (CAReS)
Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th
GlobeNewsWire
22 сент 2022 г. в 09:00
SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it will be presenting at the 2022 Ladenburg Thalmann Healthcare Conference being held on September 29, 2022 at the Sofitel Hotel in New York City.
Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
07 сент 2022 г. в 08:30
SOLANA BEACH, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12 - 14, 2022. The event will include virtual participation as well as in-person participation at the Lotte New York Palace Hotel in New York City.
Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study
Zacks Investment Research
17 авг 2022 г. в 13:33
Artelo Biosciences (ARTL) reports positive pre-clinical data from one of its FABP5 inhibitors in anxiety-related disorders. Stock up.